|
| Press Releases |
|
 |
|
| Sunday, May 5, 2024 |
|
|
健倍苗苗發佈盈喜 |
| 健倍苗苗（保健）有限公司 （「健倍苗苗」或「公司」；股份代號：2161，連同其附屬公司統稱「集團」） 為香港品牌保健品的領先營銷商及分銷商，集團發佈盈喜預告。根據集團對截至二零二四年三月三十一日止年度的未經審核綜合管理賬目的初步審閱及公司董事會目前可得的資料，集團預期截至二零二四年三月三十一日止年度的股東應佔綜合溢利（「綜合溢利」）將較去年同期增加不少於120%。 more info >> |
|
|
JBM Healthcare Issues Positive Profit Alert |
| JBM (Healthcare) Limited has announced a positive profit alert. Based on a preliminary review of the unaudited consolidated management accounts of the Group for the financial year ended 31 March 2024 and the information currently available to the board of directors of the Company, the Group is expected to record an increase in the consolidated profit attributable to shareholders for the year ended 31 March 2024 ("Consolidated Profit") by not less than 120% as compared to that for the same period last year. more info >> |
|
| Wednesday, November 22, 2023 |
|
|
健倍苗苗公布二零二四财年中期业绩 |
健倍苗苗（保健）有限公司 （「健倍苗苗」或「公司」；股份代号：2161，连同其附属公司统称「集团」） 为香港品牌保健品的领先营销商及分销商，集团今天公布截至二零二三年九月三十日止六个月（「报告期」）的中期业绩。
more info >> |
|
|
健倍苗苗公佈二零二四財年中期業績 |
| 健倍苗苗（保健）有限公司 （「健倍苗苗」或「公司」；股份代號：2161，連同其附屬公司統稱「集團」） 為香港品牌保健品的領先行銷商及分銷商，集團今天公佈截至二零二三年九月三十日止六個月（「報告期」）的中期業績。 more info >> |
|
|
JBM Healthcare Announces FY2024 Interim Results |
| JBM (Healthcare) Limited ("JBM Healthcare" or the "Company"; Stock Code: 2161, together with its subsidiaries, the "Group"), a leading branded healthcare products marketer and distributor in Hong Kong, today announced the interim results of the Group for the six months ended 30 September 2023 (the "Reporting Period"). more info >> |
|
| Thursday, June 15, 2023 |
|
|
健倍苗苗公布二零二三财年全年业绩 |
| 健倍苗苗（保健）有限公司（「健倍苗苗」或「公司」；股份代号：2161，连同其附属公司统称「集团」）为香港品牌保健品的领先营销商及分销商，集团今天公布截至二零二三年三月三十一日止年度（「二零二三财年」或「报告期」）的全年业绩。 more info >> |
|
|
健倍苗苗公佈二零二三財年全年業績 |
| 健倍苗苗（保健）有限公司（「健倍苗苗」或「公司」；股份代號：2161，連同其附屬公司統稱「集團」）為香港品牌保健品的領先營銷商及分銷商，集團今天公佈截至二零二三年三月三十一日止年度（「二零二三財年」或「報告期」）的全年業績。 more info >> |
|
|
JBM Healthcare Announces FY2023 Annual Results |
| JBM (Healthcare) Limited ("JBM Healthcare" or the "Company"; Stock Code: 2161, together with its subsidiaries, the "Group"), a leading branded healthcare products marketer and distributor in Hong Kong, today announced the annual results of the Group for the year ended 31 March 2023 ("FY2023" or the "Reporting Period"). more info >> |
|
| Friday, November 25, 2022 |
|
|
健倍苗苗公布二零二三财年中期业绩 |
健倍苗苗（保健）有限公司 （「健倍苗苗」或「集团」；股份代号：2161.HK） 为香港领先的品牌医疗保健品推广商及分销商，集团今天公布截至二零二二年九月三十日止六个月（「报告期」）的中期业绩。
more info >> |
|
|
健倍苗苗公佈二零二三財年中期業績 |
| 健倍苗苗（保健）有限公司 （「健倍苗苗」或「集團」；股份代號：2161.HK） 為香港領先的品牌醫療保健品推廣商及分銷商，集團今天公佈截至二零二二年九月三十日止六個月（「報告期」）的中期業績。 more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
analytica Hanoi 2026 Makes Its Debut, Bringing the Global Science and Laboratory Platform to Northern Vietnam
Feb 25, 2026 19:57 HKT/SGT
|
|
|
HKTDC welcomes the 2026-27 Budget
Feb 25, 2026 18:29: JST
|
|
|
周大福人壽支持《財政預算案》有關跨境安老、落實《香港可持續披露準則》以及推動體育普及化、盛事化等措施
Feb 25, 2026 18:07 HKT/SGT
|
|
|
HKTDC welcomes the 2026-27 Budget
Feb 25, 2026 17:29 HKT/SGT
|
|
|
NEC Implements AI Code Review Service "Metabob," Reducing Technical Verification Time by Up to 66%
Feb 25, 2026 18:00 JST
|
|
|
維昇藥業（2561.HK）維臻高(R)獲批：重長效生長激素王者登場 重構百億市場的商業天花板
Feb 25, 2026 14:58 HKT/SGT
|
|
|
Shoucheng Holdings (00697.HK) Sees Long-Term International Capital Rotation as Robotics Portfolio Enters Harvest Phase
Feb 25, 2026 12:23 HKT/SGT
|
|
|
首程控股（00697.HK）迎來國際長線接盤 機器人產業生態進入價值收割期
Feb 25, 2026 12:23 HKT/SGT
|
|
|
首程控股（00697.HK）迎来国际长线接盘 机器人产业生态进入价值收割期
Feb 25, 2026 12:23 HKT/SGT
|
|
|
ベイシアのスーパーマーケット内の冷蔵・冷凍庫の温度点検・記録業務を富士通のIoT可視化ソリューションにより自動化
Feb 25, 2026 12:00: JST
|
|
|
Beisia Automates Supermarket Refrigerator Temperature Monitoring and Recording with Fujitsu's IoT Visualization Solution
Feb 25, 2026 12:00 JST
|
|
|
國泰君安國際獲批使用SIMM 衍生品風險管理接軌國際標準
Feb 25, 2026 10:34 HKT/SGT
|
|
|
国泰君安国际获批使用SIMM 衍生品风险管理接轨国际标准
Feb 25, 2026 10:34 HKT/SGT
|
|
|
CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China
Feb 24, 2026 22:30: JST
|
|
|
CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China
Feb 24, 2026 21:30 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
